Genitourinary Malignancies Branch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genitourinary malignancies branch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genitourinary Malignancies Branch Today - Breaking & Trending Today

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma. ....

United States , San Francisco , Toni Choueiri , Dorothy Byrne , Paulv Viscuse , Robert Motzer , Nancy Kohlberg , Harvard Medical School , Genitourinary Tumors Multidisciplinary Clinic Center , Memorial Sloan Kettering Cancer Center , International Metastatic Renal Cell Carcinoma Database Consortium , Lank Center , Cancer Research Of The National Institute , Genitourinary Oncology Service , Genitourinary Oncology At Dana Farber Cancer Institute , University Of Virginia , National Clinical Trials Network , Cancers Symposium , Andrea Apolo , Bladder Cancer Section , Genitourinary Malignancies Branch , Bladder Cancer , Cancer Research , National Cancer Institute , Kidney Cancer , Dorothy Byrne Chair ,

Pembrolizumab Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma

The late-breaking data at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium included the results of KEYNOTE-123 for locally advanced resectable urothelial carcinoma. ....

United States , National Cancer Institute , Merck Research Laboratories , National Institutes Of Health , Clinical Oncology Genitourinary Cancers , After Surgery , Localized Muscle Invasive Bladder Cancer , Locally Advanced Urothelial , National Cancer , Completion Date , Bladder Cancer Section , Genitourinary Malignancies Branch , National Institutes ,

AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial Cancer

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point. ....

United States , Johns Hopkins University , Max Kates , Genitourinary Malignancies Branch , National Cancer Institute , Drug Administration , Bladder Cancer Program At Johns Hopkins University , Cancer Research , Clinical Oncology Genitourinary Cancer , Bladder Cancer Section , Bacillus Calmette Gu , Bladder Cancer Program , Bladder Cancer , Alignant Bladder Neoplasm , Urothelial Cancer , Alignant Neoplasia , Alignant Neoplasm , Biologic Therapy , Thyroid Disorder , Thyroid Disease , Thyroid Dysfunction , Urinary Bladder , Adjuvant Therapy ,

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma. ....

National Institutes Of Health , Genitourinary Malignancies Branch , Bladder Cancer Section , Bladder Cancer , Genitourinary Tumors Multidisciplinary Clinic , National Institutes , Andreab Apolo , Ambassador Alliance A031501 Trial , Adjuvant Pembrolizumab , Locally Advanced Muscle Invasive Urothelial Carcinoma ,

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. ....

United States , Cancer Research Of The National Institute , American Society Of Clinical Oncology , Development Agreement , National Cancer Institute , National Institutes Of Health , Alliance For Clinical Trials In Oncology , Clinical Trials , Clinical Oncology , Cancers Symposium , Bladder Cancer Section , Genitourinary Malignancies Branch , Bladder Cancer , Genitourinary Tumors Multidisciplinary Clinic , Cancer Research , National Cancer , National Institutes , Cooperative Research , Bladder Cancer , Pd L1 ,